Literature DB >> 24346414

Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome.

Anne I J Arens1, Esther G C Troost, Bianca A W Hoeben, Willem Grootjans, John A Lee, Vincent Grégoire, Mathieu Hatt, Dimitris Visvikis, Johan Bussink, Wim J G Oyen, Johannes H A M Kaanders, Eric P Visser.   

Abstract

PURPOSE: Radiotherapy of head and neck cancer induces changes in tumour cell proliferation during treatment, which can be depicted by the PET tracer (18)F-fluorothymidine (FLT). In this study, three advanced semiautomatic PET segmentation methods for delineation of the proliferative tumour volume (PV) before and during (chemo)radiotherapy were compared and related to clinical outcome.
METHODS: The study group comprised 46 patients with 48 squamous cell carcinomas of the head and neck, treated with accelerated (chemo)radiotherapy, who underwent FLT PET/CT prior to treatment and in the 2nd and 4th week of therapy. Primary gross tumour volumes were visually delineated on CT images (GTV CT). PVs were visually determined on all PET scans (PV VIS). The following semiautomatic segmentation methods were applied to sequential PET scans: background-subtracted relative-threshold level (PV RTL), a gradient-based method using the watershed transform algorithm and hierarchical clustering analysis (PV W&C), and a fuzzy locally adaptive Bayesian algorithm (PV FLAB).
RESULTS: Pretreatment PV VIS correlated best with PV FLAB and GTV CT. Correlations with PV RTL and PV W&C were weaker although statistically significant. During treatment, the PV VIS, PV W&C and PV FLAB significant decreased over time with the steepest decline over time for PV FLAB. Among these advanced segmentation methods, PV FLAB was the most robust in segmenting volumes in the third scan (67 % of tumours as compared to 40 % for PV W&C and 27 % for PV RTL). A decrease in PV FLAB above the median between the pretreatment scan and the scan obtained in the 4th week was associated with better disease-free survival (4 years 90 % versus 53 %).
CONCLUSION: In patients with head and neck cancer, FLAB proved to be the best performing method for segmentation of the PV on repeat FLT PET/CT scans during (chemo)radiotherapy. This may potentially facilitate radiation dose adaptation to changing PV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24346414     DOI: 10.1007/s00259-013-2651-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma.

Authors:  Habib Zaidi; Mehrsima Abdoli; Carolina Llina Fuentes; Issam M El Naqa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05       Impact factor: 9.236

Review 2.  Repopulation of cancer cells during therapy: an important cause of treatment failure.

Authors:  John J Kim; Ian F Tannock
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

3.  A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET.

Authors:  Mathieu Hatt; Catherine Cheze le Rest; Alexandre Turzo; Christian Roux; Dimitris Visvikis
Journal:  IEEE Trans Med Imaging       Date:  2009-01-13       Impact factor: 10.048

4.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-23       Impact factor: 9.236

5.  Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology.

Authors:  Mathieu Hatt; Dimitris Visvikis; Nidal M Albarghach; Florent Tixier; Olivier Pradier; Catherine Cheze-le Rest
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-02       Impact factor: 9.236

6.  18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging.

Authors:  Elizabeth H Dibble; Ana C Lara Alvarez; Minh-Tam Truong; Gustavo Mercier; Earl F Cook; Rathan M Subramaniam
Journal:  J Nucl Med       Date:  2012-04-09       Impact factor: 10.057

7.  18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.

Authors:  Bianca A W Hoeben; Esther G C Troost; Paul N Span; Carla M L van Herpen; Johan Bussink; Wim J G Oyen; Johannes H A M Kaanders
Journal:  J Nucl Med       Date:  2013-01-23       Impact factor: 10.057

8.  Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.

Authors:  Adrianus J de Langen; Bianca Klabbers; Mark Lubberink; Ronald Boellaard; Marieke D Spreeuwenberg; Ben J Slotman; Remco de Bree; Egbert F Smit; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-18       Impact factor: 9.236

9.  Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.

Authors:  Linda Heijmen; Lioe-Fee de Geus-Oei; Johannes H W de Wilt; Dimitris Visvikis; Mathieu Hatt; Eric P Visser; Johan Bussink; Cornelis J A Punt; Wim J G Oyen; Hanneke W M van Laarhoven
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-04       Impact factor: 9.236

10.  Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.

Authors:  Yusuf Menda; Laura L Boles Ponto; Kenneth J Dornfeld; Timothy J Tewson; G Leonard Watkins; Michael K Schultz; John J Sunderland; Michael M Graham; John M Buatti
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

View more
  14 in total

1.  Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer.

Authors:  Nai-Ming Cheng; Yu-Hua Dean Fang; Li-yu Lee; Joseph Tung-Chieh Chang; Din-Li Tsan; Shu-Hang Ng; Hung-Ming Wang; Chun-Ta Liao; Lan-Yan Yang; Ching-Han Hsu; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-23       Impact factor: 9.236

Review 2.  PET imaging biomarkers in head and neck cancer.

Authors:  Sarah Differding; François-Xavier Hanin; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

Review 3.  Biological imaging in clinical oncology: radiation therapy based on functional imaging.

Authors:  Yo-Liang Lai; Chun-Yi Wu; K S Clifford Chao
Journal:  Int J Clin Oncol       Date:  2016-07-06       Impact factor: 3.402

4.  Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211.

Authors:  Mathieu Hatt; John A Lee; Charles R Schmidtlein; Issam El Naqa; Curtis Caldwell; Elisabetta De Bernardi; Wei Lu; Shiva Das; Xavier Geets; Vincent Gregoire; Robert Jeraj; Michael P MacManus; Osama R Mawlawi; Ursula Nestle; Andrei B Pugachev; Heiko Schöder; Tony Shepherd; Emiliano Spezi; Dimitris Visvikis; Habib Zaidi; Assen S Kirov
Journal:  Med Phys       Date:  2017-05-18       Impact factor: 4.071

Review 5.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.

Authors:  Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

6.  PET-based prognostic survival model after radiotherapy for head and neck cancer.

Authors:  Joël Castelli; A Depeursinge; A Devillers; B Campillo-Gimenez; Y Dicente; J O Prior; E Chajon; F Jegoux; C Sire; O Acosta; E Gherga; X Sun; B De Bari; J Bourhis; R de Crevoisier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-21       Impact factor: 9.236

7.  18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer.

Authors:  Charline Lasnon; Mohamed Majdoub; Brice Lavigne; Pascal Do; Jeannick Madelaine; Dimitris Visvikis; Mathieu Hatt; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-21       Impact factor: 9.236

Review 8.  What Do We Measure in Oncology PET?

Authors:  Kyoungjune Pak; Seong-Jang Kim
Journal:  Nucl Med Mol Imaging       Date:  2016-04-18

9.  Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III.

Authors:  Marie-Charlotte Desseroit; Dimitris Visvikis; Florent Tixier; Mohamed Majdoub; Rémy Perdrisot; Rémy Guillevin; Catherine Cheze Le Rest; Mathieu Hatt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-20       Impact factor: 9.236

10.  3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.

Authors:  Haojun Chen; Yimin Li; Hua Wu; Long Sun; Qin Lin; Long Zhao; Hanxiang An
Journal:  Strahlenther Onkol       Date:  2014-08-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.